In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Femasys (FEMY – Research Report). The company’s shares opened today at $0.40.
McCarthy covers the Healthcare sector, focusing on stocks such as Daré Bioscience, SELLAS Life Sciences Group, and Achieve Life Sciences. According to TipRanks, McCarthy has an average return of -30.7% and a 20.68% success rate on recommended stocks.
Femasys has an analyst consensus of Strong Buy, with a price target consensus of $7.50, implying a 1,755.98% upside from current levels. In a report released yesterday, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $5.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $2.11 and a one-year low of $0.32. Currently, Femasys has an average volume of 3.7M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Femasys Inc is a biomedical company focused on transforming women’s healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. Its mission is to provide women with minimally-invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics.
Read More on FEMY:
- Femasys reports Q2 EPS (22c), consensus (19c)
- Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2023 and Provides Corporate Update
- Femasys initiates enrollment in trial of its FemBloc
- Femasys Initiates Enrollment in Pivotal Trial of its Permanent Birth Control Candidate FemBloc
- Femasys announces notice of allowance for U.S. patent for FemBloc
